Formycon AG logo

FYB - Formycon AG News Story

€29.2 -0.8  -2.7%

Last Trade - 01/10/20

Sector
Healthcare
Size
Small Cap
Market Cap £272.2m
Enterprise Value £253.8m
Revenue £35.4m
Position in Universe 552nd / 1043

BRIEF-Formycon Starts Antibody-Based Drug Development For COVID-19

Wed 29th April, 2020 6:35am
April 29 (Reuters) - FORMYCON AG  FYB.DE :
    * STARTS ANTIBODY-BASED DRUG DEVELOPMENT FOR COVID-19
    * FORMYCON AG - RESULTS OF PRECLINICAL DEVELOPMENT ARE
EXPECTED IN
Q4 OF 2020
    * FORMYCON AG - DEPENDING ON OUTCOME OF PRECLINICAL PHASE,
CLINICAL TESTING COULD BE INITIATED IN Q3 OF 2021

Source text for Eikon:  ID:nEQb2XTy3a 
Further company coverage:  FYB.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.